Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study.
Morgia G, Mucciardi G, Galì A, Madonia M, Marchese F, Di Benedetto A, Romano G, Bonvissuto G, Castelli T, Macchione L, Magno C. Morgia G, et al. Among authors: madonia m. Urol Int. 2010;84(4):400-6. doi: 10.1159/000302716. Epub 2010 Mar 24. Urol Int. 2010. PMID: 20332612 Clinical Trial.
Tailored treatment including radical prostatectomy and radiation therapy + androgen deprivation therapy versus exclusive radical prostatectomy in high-risk prostate cancer patients: results from a prospective study.
Castelli T, Russo GI, Favilla V, Urzi D, Spitaleri F, Reale G, Giardina R, Saita A, Madonia M, Cimino S, Morgia G. Castelli T, et al. Among authors: madonia m. Int Braz J Urol. 2014 May-Jun;40(3):322-9. doi: 10.1590/S1677-5538.IBJU.2014.03.05. Int Braz J Urol. 2014. PMID: 25010298 Free article.
Serenoa repens + selenium + lycopene vs tadalafil 5 mg for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: a Phase IV, non-inferiority, open-label, clinical study (SPRITE study).
Morgia G, Vespasiani G, Pareo RM, Voce S, Madonia M, Carini M, Ingrassia A, Terrone C, Gentile M, Carrino M, Giannantoni A, Blefari F, Arnone S, Santelli G, Russo GI; SPRITE investigators. Morgia G, et al. Among authors: madonia m. BJU Int. 2018 Aug;122(2):317-325. doi: 10.1111/bju.14209. Epub 2018 Apr 16. BJU Int. 2018. PMID: 29569389 Clinical Trial.
Unusual presentation of tuberous sclerosis complex.
Favilla V, Cimino S, Castelli T, Marchese F, Russo GI, Russo M, Madonia M, Morgia G. Favilla V, et al. Among authors: madonia m. Urology. 2012 Oct;80(4):e39-40. doi: 10.1016/j.urology.2012.06.016. Epub 2012 Aug 15. Urology. 2012. PMID: 22901821 No abstract available.
New advances in clinical biomarkers in testis cancer.
Favilla V, Cimino S, Madonia M, Morgia G. Favilla V, et al. Among authors: madonia m. Front Biosci (Elite Ed). 2010 Jan 1;2(2):456-77. doi: 10.2741/e105. Front Biosci (Elite Ed). 2010. PMID: 20036893 Free article. Review.
86 results